| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 20 Jul 2026 | 9 Jul 2026 |
| Venus Remedies Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2026 inter alia to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 20th July 2026 inter alia: As per the pdf enclosed. (As per BSE Announcement dated on: 20.07.2026) 1. To consider and approve Unaudited Standalone and Consolidated Financial Results for the period ended on 30th June 2026. 2. Any other business with the permission of Chair. | ||
| Board Meeting | 26 May 2026 | 15 May 2026 |
| Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 inter alia to consider and approve Board meeting scheduled for 26th May 2026 to consider agenda as given in enclosed document. Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Board meeting scheduled for 26th May 2026 to consider agenda as given in enclosed document. (As Per BSE Announcement Dated On : 15.05.2026) Outcome Of Board Meeting Dated 26.05.2026. (As per BSE announcement dated on :26.05.2026) | ||
| Board Meeting | 29 Jan 2026 | 19 Jan 2026 |
| Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 inter alia to consider and approve The meeting of Board of Directors is scheduled to be held on 29th January 2026 inter alia: 1. To consider and approve Unaudited Standalone and Consolidated Financial Results for the period ended on 31st December 2025. 2. Any other business with the permission of Chair. | ||
| Board Meeting | 10 Nov 2025 | 27 Oct 2025 |
| Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2025 ,inter alia, to consider and approve Board Meeting scheduled to be held on 10th November 2025 This has reference to the meeting of Board of Directors held on 10th November 2025 inter alia considered and approved Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended on 30th September 2025 along with Limited Review report. Unaudited Financial Results for the quarter and half year ended on 30th September 2025 along with the Limited Review report are enclosed herewith. Meeting commenced at 02:45 pm and concluded at 05.55 pm Unaudited Financial Results as on 30th September 2025 (As Per BSE Announcement Dated on:10.11.2025) | ||
| Board Meeting | 1 Aug 2025 | 22 Jul 2025 |
| Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2025 inter alia to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 1st August 2025 inter alia: 1. To consider and approve Unaudited Standalone and Consolidated Financial Results for the period ended on 30th June 2025. 2. Any other business with the permission of Chair. This has reference to the meeting of Board of Directors held on 1st August 2025 inter alia considered and approved Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on 30th June 2025 along with Limited Review report. Unaudited Financial Results for the quarter ended on 30th June 2025 along with the Limited Review report are enclosed herewith. (As per BSE Announcement Dated on 01/08/2025) | ||
The Unit-II Baddi plant, which got the renewed certification, has state-of-art infrastructure and state-of-the-art manufacturing technology to cater to complex therapeutic segments in an efficient manner.
The company is now set to further expand into Eastern Europe as this recognition ensures patients and healthcare providers have access to reliable and effective antibiotics.
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
